Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 4Terminated 2Unknown 1Recruiting 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2Genitourinary 1Dermatologic 1Breast 1

Conditions

Breast Neoplasms 1872Triple Negative Breast Neoplasms 126Neoplasms 74Ovarian Neoplasms 56Neoplasm Metastasis 55Colorectal Neoplasms 54Prostatic Neoplasms 53Lung Neoplasms 51Stomach Neoplasms 45Pancreatic Neoplasms 43Motor Activity 41Colonic Neoplasms 41Lymphedema 35Breast Cancer Female 32Advanced Breast Cancer 32Carcinoma, Non-Small-Cell Lung 31Endometrial Neoplasms 28Melanoma 27Breast Diseases 26Head and Neck Neoplasms 25Cardiotoxicity 25HER2-positive Breast Cancer 22Uterine Cervical Neoplasms 21Brain Neoplasms 21Breast Cancer Lymphedema 20Pain 19Fatigue 19Esophageal Neoplasms 19Breast Neoplasms, Male 19Urinary Bladder Neoplasms 18

Interventions

Pyridoxine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Hand-Foot Syndrome × Breast × Clear all
NCT00559858 2013-08-02

Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Capecitabine for Advanced Colorectal Cancer or Breast Cancer

National Cancer Institute (NCI)

Phase 3 Unknown
270 enrolled
BreastGastrointestinal

Breast Neoplasms, Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Breast Neoplasms, Male, Hand-Foot Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡